InStyle Magazine’s Editor in Chief and Host of Ladies First, Laura Brown Moderated the Intimate Conversation
Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), headlined Collision 2021 and discussed the changing landscape of beauty, health and wellness. Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Nancy Duitch, Founder/CEO Sera Labs/CURE Pharmaceutical Chief Strategic Officer kept the 40,000 attendee conference engaged in a funny, smart and energetic conversation about life, wellness and technology. Collision is North America’s fastest-growing tech conference and brings together the world’s most sought-after founders, tech companies, and game-changing entrepreneurs of our time.
The lively discussion addressed the inception of the Kidman/Seratopical partnership and the brand’s Q2 plant-based product launch, which is ‘Revolutionary.” Duitch and Kidman also discussed some of Kidman’s favorite Seratopical products and CURE’s proprietary polymer (PꝫP complex) delivery systems which marry nature and science to create the most efficacious and nourishing products on the market.
“Our presence at Collision created more forward business momentum than we could have ever expected. Many people were able to learn about the future of wellness and our cutting-edge technology. We are truly creating what will become the new standard for beauty, health and wellness products,” said Duitch, Sera Labs CEO/Founder and CURE Pharmaceutical Chief Strategic Officer.
Watch the Collision 2021 video here, https://curepharmaceutical.com/video/collision-conference-2021/
About Sera Labs
Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD and clean plant-based products. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical™, SeraLabs™, and Gordon’s Herbals™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness. Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopical.com, seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: firstname.lastname@example.org.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005293/en/
Chief Business Officer, CURE Pharmaceutical